The interpretation of Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: ASCO-OH (CCO) Guideline Update
Bone-modifying agents (BMAs), including bisphosphonate (BP) and denosumab, can reduce bone-related events caused by breast cancer bone metastasis. “Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: ASCO-OH (CCO) Guideline Update” was published in Journal of Clinical O...
Saved in:
Main Author: | LU Yujie, ZHU Siji |
---|---|
Format: | Article |
Language: | zho |
Published: |
Editorial Office of Journal of Surgery Concepts & Practice
2024-09-01
|
Series: | Waike lilun yu shijian |
Subjects: | |
Online Access: | https://www.qk.sjtu.edu.cn/jscp/fileup/1007-9610/PDF/1737619523177-1505710455.pdf |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Effect of bisphosphonate on bone microstructure, mechanical strength in osteoporotic rats by ovariectomy
by: Yuzhu Wang, et al.
Published: (2024-09-01) -
Nitrogen-containing bisphosphonate for vascular calcification: animal experiments, systematic review and meta-analysis
by: Wei Xu, et al.
Published: (2025-01-01) -
Health-related quality of life following bisphosphonate therapy in individuals with Paget’s disease of bone – A study from a teaching hospital in Southern India
by: Fibi K. Ninan, et al.
Published: (2025-01-01) -
Cytotoxic Activity of Bisphosphonic Derivatives Obtained by the Michaelis–Arbuzov or the Pudovik Reaction
by: Zsuzsanna Szalai, et al.
Published: (2025-01-01) -
Adjuvant chemotherapy followed by concurrent chemoradiation is associated with improved survival for resected stage I‐II pancreatic cancer
by: Sung Jun Ma, et al.
Published: (2019-03-01)